Abstract
Purpose: To investigate the relationship between prognosis of gastric cancer (GC) and the expression of P53, Epidermal growth factor receptor (EGFR), Human epidermal growth factor receptor-2 (HER-2), and Vascular endothelial growth factor (VEGF).Methods: One hundred and forty-seven patients admitted to People's Liberation Army General Hospital (Beijing, China) with diagnosis of locally advanced GC were enrolled in the study. Follow-up data were obtained by outpatient review or telephone follow-up. Expressions of P53, EGFR, HER-2 and VEGF were determined by immunohistochemical staining. The relationship between protein expression, clinico-pathological factors, disease-free survival time (DFS) and overall survival (OS) were analyzed.Results: The expressions of EGER, HER-2, P53 and VEGF in GC were 17.7, 17.0, 41.0 and 55.9%, respectively. The expressions of EGFR and P53 were positively correlated (r = 0.306, p < 0.05), while the expressions of VEGF and HER-2 were negatively correlated (r = -0.2, p < 0.05). The expressions of EGFR, HER-2 and VEGF were not related to the clinico-pathological factors (p > 0.05) while expression of P53 was related only to histological grade (p < 0.05). Univariate analysis showed that OS and DFS were longer (p < 0.05) when P53 was lowly expressed. Multiple-factor analysis revealed that histological grade, infiltration depth and P53 expression were independent factors that influenced DFS.Conclusion: These results indicate that the expression of P53, EGFR, HER2 and VEGF can be used to predict prognosis of GC and screening of patients’ benefits from adjuvant chemotherapy.Keywords: Gastric cancer, Prognosis, Biomarkers, Adjuvant chemotherapy
Highlights
Gastric cancer (GC) is the fifth most common malignant disease and is the third leading cause of cancer deaths in both sexes worldwide [1]
Expression of P53 was only related to the histological grade (p < 0.05)
EGER and Human epidermal growth factor receptor-2 (HER-2) proteins were located in the cell membrane and cytoplasm, while P53 and Vascular endothelial growth factor (VEGF) proteins were located in cell nucleus (Figure 1)
Summary
Gastric cancer (GC) is the fifth most common malignant disease and is the third leading cause of cancer deaths in both sexes worldwide [1]. In China, GC is currently the second most common cancer and second leading cause of cancer death [2]. Recent progress in research on recombinant humanized anti-HER2 antibody (Herceptin) in the treatment of HER2-positive expression GC has aroused considerable interest in prognosis-related biomarkers and GC sensitivity to chemotherapy [4]. Not much is known about the predictive roles of these indicators in adjuvant chemotherapy after GC surgery. Meta-analysis has proved that adjuvant treatment with 5-fluorouracil (5-FU) after radical surgery in GC was beneficial to patients’ survival [6]
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
